Issue 1/2012
Content (24 Articles)
Intra-CSF administration of chemotherapy medications
Michael P. Gabay, Jigisha P. Thakkar, Joan M. Stachnik, Susan K. Woelich, J. Lee Villano
Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats
Nawale Hajjaji, Pierre Besson, Philippe Bougnoux
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53
E. Gabriela Chiorean, Sonal Sanghani, Marissa A. Schiel, Menggang Yu, Matthew Burns, Yan Tong, David T. Hinkle, Nicki Coleman, Bruce Robb, Julia LeBlanc, Romnee Clark, Jose Bufill, Colleen Curie, Patrick J. Loehrer, Higinia Cardenes
Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies
Muneaki Shimada, Hiroyuki Fujiwara, Shinya Sato, Tetsuro Oishi, Hiroaki Itamochi, Shizuo Machida, Yuji Takei, Tasuku Harada, Mitsuaki Suzuki, Junzo Kigawa
Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine
Hannelouise Kissow, Niels-Erik Viby, Bolette Hartmann, Jens Juul Holst, Michael Timm, Lars Thim, Steen Seier Poulsen
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
Maryam B. Lustberg, Shubham Pant, Amy S. Ruppert, Tong Shen, Yong Wei, Ling Chen, Lisa Brenner, Donna Shiels, Rhonda R. Jensen, Michael Berger, Ewa Mrozek, Bhuvaneswari Ramaswamy, Michael Grever, Jessie L. Au, M. Guillaume Wientjes, Charles L. Shapiro
Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors
Jin Li, Yanfei Liu, Jun Qian, Lennie Wu, John Kemp, Masahiro Nii, Helen Tomkinson, Yunxia Zuo, Malcolm Ranson, Michiyuki Usami
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors
S. Leong, S. G. Eckhardt, E. Chan, W. A. Messersmith, J. Spratlin, D. R. Camidge, S. Diab, R. Khosravan, X. Lin, E. Chow Maneval, A. C. Lockhart
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
Solai Elango Damodaran, Suresh Chandra Pradhan, Gurusamy Umamaheswaran, Dharanipragada Kadambari, K. Sathyanarayana Reddy, Chandrasekaran Adithan
Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children’s oncology group
Alena Y. Z. Edwards, Jeffrey M. Skolnik, Erin Dombrowsky, Dimple Patel, Jeffrey S. Barrett
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
Gordana Vlahovic, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S. Yousuf Zafar, Angeles Alvarez-Secord, Jon Gockerman, Alexander N. Starodub, Neal E. Ready, Elizabeth L. Anderson, Johanna C. Bendell, Herbert I. Hurwitz
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers
Yazdi K. Pithavala, Ying Chen, Melvin Toh, Paulina Selaru, Robert R. LaBadie, May Garrett, Brian Hee, Janessa Mount, Grace Ni, Karen J. Klamerus, Michael A. Tortorici
Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro
B. A. Kamen, A. K. Smith
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
Matthew G. Fury, Eric Sherman, Alan Ho, Nora Katabi, Camelia Sima, Katherine W. Kelly, Oby Nwankwo, Sofia Haque, David G. Pfister
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas
Rachel Grossman, Michelle A. Rudek, Harry Brastianos, Patti Zadnik, Henry Brem, Betty Tyler, Jaishri O. Blakeley
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer
Mohamad Farid, Balram Chowbay, Xiangai Chen, Sze Huey Tan, Saminathan Ramasamy, Wen Hsin Koo, Han Chong Toh, Su Pin Choo, Simon Yew Kuang Ong
Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics
Pradeep B. Lukka, James W. Paxton, Philip Kestell, Bruce C. Baguley
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study
N. Kentepozidis, A. Soultati, S. Giassas, N. Vardakis, A. Kalykaki, A. Kotsakis, E. Papadimitraki, N. Pantazopoulos, V. Bozionellou, V. Georgoulias
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer
N. Karachaliou, N. Ziras, K. Syrigos, K. Tryfonidis, E. Papadimitraki, E. Kontopodis, V. Bozionelou, A. Kalykaki, V. Georgoulias, D. Mavroudis
The minimal impact of food on the pharmacokinetics of ridaforolimus
Mark Stroh, Xiaodong Li, Sabrina Marsilio, Deborah Panebianco, Amy Johnson-Levonas, Axel Juan, Keith Orford, Nancy Agrawal, Michele Trucksis, John A. Wagner, Gail Murphy, Marian Iwamoto
Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers
Gavin Choy, Rajashree Joshi-Hangal, Aram Oganesian, Gil Fine, Scott Rasmussen, Joanne Collier, James Kissling, Amarpal Sahai, Mohammad Azab, Sanjeev Redkar
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor
Richat Abbas, Bruce A. Hug, Cathie Leister, Daryl Sonnichsen
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
Abdulateef O. Aregbe, Eric A. Sherer, Merrill J. Egorin, Howard I. Scher, David B. Solit, Ramesh K. Ramanathan, Suresh Ramalingam, Chandra P. Belani, Percy S. Ivy, Robert R. Bies
The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response
Trevor G. Glaros, Luke H. Stockwin, Michael E. Mullendore, Brian Smith, Bethanie L. Morrison, Dianne L. Newton